Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai, together with its US subsidiary Eisai Inc and Arena Pharmaceuticals have revealed the results from the two-year BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial with Lorcaserin, a new obesity and weight management drug.
Subscribe to our email newsletter
Eisai Inc has received exclusive rights to market and distribute Lorcaserin in the US from Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals.
Eisai said that the Lorcaserin BLOOM study demonstrated greater weight loss and improved maintenance of weight loss compared to placebo. Lorcaserin also improved values for biomarkers that may be predictive of future cardiovascular events, including lipid levels, insulin resistance, levels of inflammatory markers and blood pressure.
The BLOOM trial was a double-blind, randomised, placebo-controlled trial. Lorcaserin patients who completed the trial lost 8.2% of the body weight, or about 8.2kg, as compared to 3.2%, or about 3.2kg, in the placebo group.
Eisai added that Lorcaserin also decreased waist circumference, BMI, glycemic parameters, high-sensitivity C-reactive protein, and fibrinogen levels compared to placebo. Total cholesterol, LDL cholesterol and triglyceride levels at Year 1 were also lower in the Lorcaserin group than in the placebo group. Lorcaserin did not increase heart rate or blood pressure; rather, heart rate, systolic blood pressure and diastolic blood pressure decreased slightly.